Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India

Tropical Medicine and International Health

Volumn 14, Issue 1, 2009, Pages 88-92

  Olliaro, P ^a,b   Sundar, S ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BANARAS HINDU UNIVERSITY   (India)

Author keywords

Amfotericina B liposomal; Costes de tratamiento; Leishmaniasis visceral; Miltefosina; Paromomicina; Resistencia a antimonio

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MILTEFOSINE; PAROMOMYCIN;

COST; DRUG; HEALTH CARE; INFECTIOUS DISEASE; POPULATION STRUCTURE; PUBLIC HEALTH;

ADOLESCENT; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CHILD; CONTROLLED STUDY; DOSE CALCULATION; DRUG COST; DRUG DOSE COMPARISON; FEMALE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AMPHOTERICIN B; ANTHROPOMETRY; ANTIPROTOZOAL AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; FEMALE; HUMANS; INDIA; INFANT; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; MIDDLE AGED; PAROMOMYCIN; PHOSPHORYLCHOLINE; SEX DISTRIBUTION;

ASIA; BIHAR; EURASIA; INDIA; SOUTH ASIA;

EID: 58449083522     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2008.02195.x     Document Type: Article

References (13)

1. Bhattacharya SK, Sinha PK, Sundar S et al. (2007) Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. Journal of Infectious Diseases 196, 591 598.
2. Chappuis F, Sundar S, Hailu A et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nature Review Microbiology 5, 873 882.
3. Olliaro PL, Guerin PJ, Gerstl S et al. (2005) Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India 1980-2004. Lancet Infectious Diseases 5, 763 774.
4. Sundar S Olliaro PL (2007) Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Therapeutics and Clinical Risk Management 3, 733 740.
5. Sundar S, Jha TK, Thakur CP et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 347, 1739 1746.
6. Sundar S, Mehta H, Suresh AV et al. (2004) Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clinical Infectious Diseases 38, 377 383.
7. Sundar S, Jha TK, Thakur CP et al. (2007) Injectable paromomycin for Visceral leishmaniasis in India. New England Journal of Medicine 356, 2571 2581.
8. Thakur CP (2000) Socio-economics of visceral leishmaniasis in Bihar (India). Transactions of the Royal Society of Tropical Medicine and Hygiene 94, 156 157.
9. Thakur CP, Pandey AK, Sinha GP et al. (1996) Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Transactions of the Royal Society of Tropical Medicine and Hygiene 90, 319 322.
10. WHO (2005a) WHO/TDR. Press Release: Elimination of Kala-azar from Endemic Countries in the South-East Asia Region. Health Ministers' Sign Memorandum of Understanding. Geneva/New Delhi, May 18 2005. http://www.who.int/tdr/diseases/ leish/press-release.htm (last accessed 10 June 2008).
11. WHO (2005b) Report of a WHO informal Consultation on "Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis". Rome, Italy, 16 April 2005. http://www.who.int/neglected-diseases/resources/AmBisomeReport.pdf.
12. WHO (2008a) Leishmaniasis Disease Burden. http://www.who.int/ leishmaniasis/burden/en/ (last accessed 10 June 2008).
13. WHO (2008b) Kala Azar: Why Kala Azar Elimination is Possible in South Asia Countries? http://www.searo.who.int/en/Section10/Section2163-11671.htm. (last accessed 10 June 2008).